Loading...

Brian Druker (OHSU) Part 3: Extending the Imatinib Paradigm

4,268 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Mar 29, 2010

https://www.ibiology.org/human-diseas...

Imatinib has become the paradigm of targeted drug development. The lessons learned from the clinical trials of imatinib treatment of chronic myeloid leukemia will be reviewed in this section. This will include examples of where imatinib has or has not worked, analysis of target expression versus activation and a discussion of how the success of imatinib can be translated to other malignancies. The section concludes with what this means for research to control or cure cancer in the coming decades.

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...